Pomerantz Law Firm Investigates Securities Claims Against Valneva SE Amidst Vaccine Concerns

Investigation into Valneva SE by Pomerantz Law Firm

Pomerantz LLP, a leading firm in corporate and securities class action litigation, has initiated an investigation concerning potential wrongful acts related to Valneva SE, traded under NASDAQ symbol VALN. This investigation aims to determine if the company or its executives have been involved in any unlawful business practices or securities fraud, particularly in light of recent safety concerns surrounding its chikungunya vaccine, IXCHIQ.

Recent Developments Leading to Investigation

On February 25, 2025, the Centers for Disease Control and Prevention (CDC) publicly announced an investigation into five hospitalizations among individuals aged 65 and older that were linked to the IXCHIQ vaccine. This notification raised significant alarm among investors and stakeholders regarding the vaccine's safety profile. Following this news, Valneva's American Depositary Receipt (ADR) saw a substantial drop of $1.06, translating to a 13.57% decline over four trading sessions, closing at $6.75 on February 28, 2025.

Additionally, on August 22, 2025, the Food and Drug Administration (FDA) declared a suspension of the marketing application for IXCHIQ due to these ongoing safety concerns. As a direct consequence of this announcement, Valneva experienced another significant drop; its ADR price fell by $2.21, equating to an 18.99% decline, to close at $9.43 per ADR on August 25, 2025.

Pomerantz's Role in the Investigation

As one of the recognized leaders in handling class action litigation, Pomerantz LLP aims to protect investors' interests who may have been adversely affected by these developments. The firm has a rich history, dating back over 85 years, in championing the rights of investors victimized by securities fraud.

Danielle Peyton, a key attorney at Pomerantz, is spearheading efforts for affected investors to join the class action lawsuit. Those with direct or indirect interests in Valneva SE are encouraged to reach out to her for guidance.

Contact Information

Investors seeking further information regarding the ongoing investigation or wishing to participate can contact Danielle Peyton directly via email at [email protected] or call at 646-581-9980, ext. 7980.

The Importance of Vigilance

This case serves as a crucial reminder for investors to remain vigilant concerning the companies they invest in, particularly when significant safety issues arise that could implicate corporate governance or management integrity.

Investors should closely monitor the outcomes of this investigation and any resulting legal proceedings that may arise as a consequence of these serious allegations against Valneva SE.

Conclusion

Pomerantz LLP remains committed to advocating for those affected by potential securities fraud and ensuring accountability in corporate America. This investigation could set a significant precedent in corporate governance and investor rights enforcement, particularly in the volatile field of biotechnology and medicinal products. As the situation develops, further updates will be provided to ensure that investors are kept informed.